IL-33 Antibody is affinity chromatography purified via peptide column.
Immunogen
Anti-IL-33 antibody was raised against a 17 amino acid synthetic peptide from near the center of human IL-33. The immunogen is located within the 150-200 amino acids of IL-33.
IL33
Reaktivität: Human
ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
WB: 1-2 μ,g/mL, IF: 20 μ,g/mL, IHC-P: 2.5 μ,g/mL.
Antibody validated: Western Blot in human and mouse samples, Immunofluorescence and Immunohistochemistry in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
IL-33 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
IL-33 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
IL-33 (IL33)
(Interleukin 33 (IL33))
Andere Bezeichnung
IL-33
Hintergrund
IL-33 Antibody: Interleukin-33 (IL-33) is a recently identified member of the IL-1 family of cytokines whose other members include IL-1α,/beta, IL-1Ra and IL-18. Its receptor has been shown to be ST2, an IL-1 receptor family member that also acts as a negative regulator of TLR-IL-1R signaling and IL-1R accessory protein (IL-1RAcP). Receptor binding of IL-33 activates NF-κ,B and MAP kinases and induces the expression of TH2-associated cytokines such as IL-4, IL-5 and IL-6. Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine. Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties.